"The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended 150 mg lamivudine/300 mg raltegravir (Dutrebis, Merck Sharp & Dohme Limited) for the treatment of HIV 1 infection in adults, adolesce"...
ZIAGEN is contraindicated in patients with:
- previously demonstrated hypersensitivity to abacavir or any other component of the products. NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status [see WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS].
- moderate or severe hepatic impairment [see DOSAGE AND ADMINISTRATION].
Last reviewed on RxList: 3/6/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Ziagen Information
Ziagen - User Reviews
Ziagen User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Get breaking medical news.